A bold new chapter in longevity science is unfolding as NewLimit, a biotech startup co‑founded by Coinbase CEO Brian Armstrong, has secured $130 million in Series B funding to develop potential age‑reversing therapies. The funding round was led by venture capital firm Kleiner Perkins, with participation from other major backers including Khosla Ventures, Founders Fund, and Dimension Capital.
Founded in 2021 alongside former GV partner Blake Byers and stem cell expert Jacob Kimmel, NewLimit is pursuing cutting‑edge approaches to epigenetic reprogramming — a technique that aims to restore aged cells to more youthful states by adjusting their genetic programming. Early lab results from the company’s prototype medicines suggest that treated liver cells can regain functions typically seen in younger cells, such as more efficient metabolic activity.
By combining AI‑driven drug discovery with biological research, NewLimit hopes to accelerate the development of treatments that could someday help extend healthy human lifespan. While human clinical trials are still several years away, this latest funding marks a significant milestone in the rapidly growing field of longevity biotech.
Source:
Read the original TechCrunch article:
https://techcrunch.com/2025/05/06/newlimit-founded-by-coinbase-ceo-brian-armstrong-raises-130m-to-develop-age-reversing-therapies/